2.4. Baseline Concentrations and Changes in IGFBP-1, IGFBP-3 and IGFBP-rp1 in Patients with T2DM After 52-Week Semaglutide and Sitagliptin Treatment. The gene discussed is IGFBP3; the disease is type 2 diabetes mellitus.